Skip to main content
. 2020 Jul 6;36(1):171–173. doi: 10.1111/jgh.15164

Table 1.

Characteristics of IBD patients in Hong Kong and Taiwan

Hong Kong (n = 2954) Taiwan TSIBD retrospective cohort (n = 2554) Taiwan TSIBD prospective cohort (n = 537)
Age † 53.36 ± 16.12 43.33 ± 18.03 43.87 ± 16.26
Male, n(%) 1766 (59.7%) 1614 (63.1%) 354 (65.9%)
Disease phenotype, n(%)

  • Crohn's disease

 1115 (39.1%) 871 (34.1%) 229 (42.6%)

  • Ulcerative colitis/IBD‐Undifferentiated

 1839 (62.3%) 1685 (65.9%) 308 (57.4%)
Medical therapy for IBD, n(%)
126 (4.3%) 1421 (55.6%) 140 (26.1%)

  • 5‐Aminosalicylate acid

 1928 (65.3%) 2381 (93.2%) 407 (75.8%)

  • Thiopurines

 1070 (36.2%) 906 (35.4%) 267 (49.7%)

  • Methotrexate

 57 (1.9%) 44 (1.7%) 7 (1.3%)

  • Tacrolimus

 17 (0.6%) 18 (0.7%) 2 (0.4%)

  • Biologics
  • ○

    Infliximab

 150 (5.1%) 24 (0.94%) 13 (2.4%)
  • ○

    Adalimumab

 130 (4.4%) 347 (13.6%) 66 (12.3%)
  • ○

    Vedolizumab

 46 (1.6%) 30 (1.2%) 198 (36.9%)
  • ○

    Ustekinumab

 49 (1.7%) 0 (0%) 4 (0.7%)

IBD, inflammatory bowel disease; TSIBD, Taiwan Society of Inflammatory Bowel Disease Registry.

†

Age was expressed as mean ± standard deviation.

‡

Corticosteroids include prednisolone (oral), budesonide and budesonide MMX (oral), and hydrocortisone (intravenous).